Format

Send to

Choose Destination
Cancer Sci. 2017 Apr;108(4):570-573. doi: 10.1111/cas.13188. Epub 2017 Apr 12.

Molecular-targeting therapies against quantitative abnormalities in gene expression with malignant tumors.

Author information

1
Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Abstract

Genetic mutations in exons of oncogenes and tumor-suppressor genes causing qualitative abnormalities result in activation of the oncogenes and inactivation of the tumor-suppressor genes, thereby causing cancer. In contrast, we have previously demonstrated that decreases in the RB promoter activity by genetic or epigenetic abnormalities can also cause carcinogenesis. In addition, activation and inactivation of a variety of oncogenes and tumor-suppressor genes finally cause quantitative abnormalities in gene expression. Interestingly, we discovered effective molecular-targeting agents, such as a novel MEK inhibitor, trametinib, by screening for agents upregulating the expression of cyclin-dependent kinase inhibitors. In the present review, we focused on the quantitative abnormalities in gene expression with carcinogenesis, and discuss the importance of normalizing the quantitative abnormalities in gene expression with several molecular-targeting agents.

KEYWORDS:

RB ; Carcinogenesis; molecular-targeting therapies; quantitative abnormalities; trametinib

PMID:
28178388
PMCID:
PMC5406604
DOI:
10.1111/cas.13188
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center